Dicerna Pharmaceuticals Inc.

26.09-0.3300-1.25%Vol 536.85K1Y Perf 32.98%
Apr 9th, 2021 16:00 DELAYED
BID26.05 ASK26.09
Open26.50 Previous Close26.42
Pre-Market- After-Market26.09
 - -  - -%
Target Price
37.86 
Analyst Rating
Strong Buy 1.09
Potential %
45.11 
Finscreener Ranking
★★+     48.95
Insiders Trans % 3/6/12 mo.
-100/-100/-97 
Value Ranking
★+     45.06
Insiders Value % 3/6/12 mo.
-100/-100/-99 
Growth Ranking
★★★     52.16
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-99 
Income Ranking
 —    -
Market Cap1.99B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
71.57 
Earnings Date
6th May 2021

Today's Price Range

25.6226.63

52W Range

16.5029.90

5 Year PE Ratio Range

-6.70-3.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.28%
1 Month
0.35%
3 Months
12.02%
6 Months
31.24%
1 Year
32.98%
3 Years
157.81%
5 Years
393.19%
10 Years
-

TickerPriceChg.Chg.%
DRNA26.09-0.3300-1.25
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
3.40
3.50
0.26
0.38
-5 636.40
Leverage Ratio 4.80
ProfitabilityValueIndustryS&P 500US Markets
-
-88.30
-86.80
-4 964.50
-69.37
RevenueValueIndustryS&P 500US Markets
130.28M
1.71
257.60
295.85
Earnings HistoryEstimateReportedSurprise %
Q04 20200.11-0.49-545.45
Q03 2020-0.17-0.29-70.59
Q02 20200.21-0.43-304.76
Q01 20200.28-0.31-210.71
Q04 2019-0.08-0.58-625.00
Q03 2019-0.30-0.45-50.00
Q02 2019-0.32-0.35-9.38
Q01 2019-0.22-0.38-72.73
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.29-1 350.00Negative
6/2021 QR-0.23-475.00Negative
12/2021 FY-1.19-48.75Negative
12/2022 FY-0.9138.10Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.28
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume536.85K
Shares Outstanding76.32M
Trades Count7.74K
Dollar Volume40.62M
Avg. Volume824.68K
Avg. Weekly Volume532.12K
Avg. Monthly Volume769.97K
Avg. Quarterly Volume828.69K

Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) stock closed at 26.09 per share at the end of the most recent trading day (a -1.25% change compared to the prior day closing price) with a volume of 537.00K shares and market capitalization of 1.99B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 302 people. Dicerna Pharmaceuticals Inc. CEO is Douglas M. Fambrough.

The one-year performance of Dicerna Pharmaceuticals Inc. stock is 32.98%, while year-to-date (YTD) performance is 18.43%. DRNA stock has a five-year performance of 393.19%. Its 52-week range is between 16.5 and 29.9, which gives DRNA stock a 52-week price range ratio of 71.57%

Dicerna Pharmaceuticals Inc. currently has a PE ratio of -16.90, a price-to-book (PB) ratio of 14.17, a price-to-sale (PS) ratio of 15.91, a price to cashflow ratio of 10.80, a PEG ratio of 2.32, a ROA of -16.60%, a ROC of -74.27% and a ROE of -74.31%. The company’s profit margin is -69.37%, its EBITDA margin is -86.80%, and its revenue ttm is $130.28 Million , which makes it $1.71 revenue per share.

Of the last four earnings reports from Dicerna Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Dicerna Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Dicerna Pharmaceuticals Inc. is Strong Buy (1.09), with a target price of $37.86, which is +45.11% compared to the current price. The earnings rating for Dicerna Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Dicerna Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Dicerna Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.75, ATR14 : 1.94, CCI20 : 36.32, Chaikin Money Flow : -0.06, MACD : 0.74, Money Flow Index : 57.75, ROC : 1.19, RSI : 55.31, STOCH (14,3) : 58.01, STOCH RSI : 0.37, UO : 54.62, Williams %R : -41.99), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Dicerna Pharmaceuticals Inc. in the last 12-months were: Adam M. Koppel (Sold 1 000 000 shares of value $23 400 000 ), Bob Brown (Option Excercise at a value of $1 175 906), Bob Brown (Sold 277 976 shares of value $6 496 273 ), Douglas M. Fambrough (Buy at a value of $180 597), Douglas M. Fambrough (Option Excercise at a value of $0), James B. Weissman (Option Excercise at a value of $219 070), James B. Weissman (Sold 77 804 shares of value $1 764 768 ), John B. Green (Option Excercise at a value of $139 651), John B. Green (Sold 25 624 shares of value $588 071 ), Regina M. Paglia (Option Excercise at a value of $617 071), Regina M. Paglia (Sold 34 619 shares of value $856 147 ), Robert D. Ciappenelli (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (90.91 %)
10 (90.91 %)
9 (100.00 %)
Moderate Buy
1 (9.09 %)
1 (9.09 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.09
Strong Buy
1.09
Strong Buy
1.00

Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. The company is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.

CEO: Douglas M. Fambrough

Telephone: +1 617 621-8097

Address: 33 Hayden Avenue, Lexington 02421, MA, US

Number of employees: 302

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

50%50%

Bearish Bullish

58%42%

News

Stocktwits